Capricor Therapeutics (NASDAQ: CAPR) reported Q2 EPS of ($0.35), $0.01 better than the analyst estimate of ($0.36). Revenue for the quarter came in at $3.97 million versus the consensus estimate of $4.41 million.

For earnings history and earnings-related data on Capricor Therapeutics (CAPR) click here.